Suppr超能文献

雌激素受体表达与高级别浆液性卵巢癌淋巴管血管侵犯风险增加。

Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.

机构信息

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, Los Angeles, CA, USA.

Department of Pathology, Mercy Medical Center, Baltimore, MD, USA.

出版信息

Gynecol Oncol. 2014 Jun;133(3):473-9. doi: 10.1016/j.ygyno.2014.03.563. Epub 2014 Mar 25.

Abstract

OBJECTIVE

Recent studies have demonstrated that lymphovascular space invasion (LVSI) is associated with increased risk of hematogenous and lymphatic metastasis and poor clinical outcome of women with epithelial ovarian cancer. Given the suspected role of estrogen in promoting ovarian cancer metastasis, we examined potential links between estrogen receptor and LVSI in high-grade serous ovarian carcinoma.

METHODS

Tumoral expression of ER, PR, p53, MDR1, EGFR, HER2, DNA ploidy, and S-phase fraction was examined for 121 cases of stage I-IV high-grade serous ovarian carcinoma samples obtained at primary cytoreductive surgery. Biomarker expression was correlated to LVSI and survival outcomes.

RESULTS

LVSI was observed in 101 (83.5%) of all cases. Immunohistochemistry of tested biomarkers showed ER (86.7%) to be the most commonly expressed followed by p53 (71.4%), HER2 (68.3%), EGFR (52.1%), MDR-1 (14.3%), and PR (8.9%). ER expression was positively correlated to PR expression (r=0.31, p=0.001). LVSI was only correlated with ER (odds ratio 6.27, 95%CI 1.93-20.4, p=0.002) but not with other biomarkers. In multivariate analysis, ER remained significantly associated with LVSI (p=0.039). LVSI remained a significant prognostic factor for decreased progression-free survival (HR 3.01, 95%CI 1.54-5.88, p=0.001) and overall survival (HR 2.69, 95%CI 1.18-6.23, p=0.021) while ER-expression did not remain as a significant variable in multivariate analysis.

CONCLUSION

Our data demonstrated that estrogen receptor was positively correlated with LVSI that was an independent prognostic indicator of poor survival outcomes of high-grade serous ovarian carcinoma. This study emphasizes the importance of estrogen pathway in promoting lymphatic or vascular spread of high-grade serous ovarian carcinoma.

摘要

目的

最近的研究表明,淋巴血管空间侵犯(LVSI)与上皮性卵巢癌患者血行和淋巴转移的风险增加以及临床结局不良有关。鉴于雌激素在促进卵巢癌转移中的可疑作用,我们研究了高分级浆液性卵巢癌中雌激素受体与 LVSI 之间的潜在联系。

方法

对 121 例初次细胞减灭术时获得的 I-IV 期高分级浆液性卵巢癌样本进行 ER、PR、p53、MDR1、EGFR、HER2、DNA 倍体和 S 期分数的肿瘤表达检测。生物标志物表达与 LVSI 和生存结果相关。

结果

所有病例中 LVSI 为 101 例(83.5%)。经测试的生物标志物的免疫组化显示 ER(86.7%)是最常见的表达,其次是 p53(71.4%)、HER2(68.3%)、EGFR(52.1%)、MDR-1(14.3%)和 PR(8.9%)。ER 表达与 PR 表达呈正相关(r=0.31,p=0.001)。LVSI 仅与 ER 相关(优势比 6.27,95%CI 1.93-20.4,p=0.002),与其他生物标志物无关。多变量分析中,ER 与 LVSI 仍显著相关(p=0.039)。LVSI 仍是无进展生存期(HR 3.01,95%CI 1.54-5.88,p=0.001)和总生存期(HR 2.69,95%CI 1.18-6.23,p=0.021)显著降低的独立预后因素,而 ER 表达在多变量分析中不再是显著变量。

结论

我们的数据表明,雌激素受体与 LVSI 呈正相关,LVSI 是高分级浆液性卵巢癌生存结局不良的独立预后指标。这项研究强调了雌激素通路在促进高级别浆液性卵巢癌淋巴管或血管扩散中的重要性。

相似文献

引用本文的文献

本文引用的文献

3
New insights on the role of hormonal therapy in ovarian cancer.激素疗法在卵巢癌中作用的新见解。
Steroids. 2013 Jun;78(6):530-7. doi: 10.1016/j.steroids.2013.01.008. Epub 2013 Feb 8.
5
Cancer statistics, 2013.癌症统计数据,2013 年。
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
6
Contemporary use of bevacizumab in ovarian cancer.贝伐珠单抗在卵巢癌中的当代应用。
Expert Opin Biol Ther. 2013 Feb;13(2):283-94. doi: 10.1517/14712598.2012.745508. Epub 2012 Nov 29.
7
8
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.PI3K/AKT/mTOR 通路作为子宫内膜癌的治疗靶点。
Clin Cancer Res. 2012 Nov 1;18(21):5856-64. doi: 10.1158/1078-0432.CCR-12-0662. Epub 2012 Oct 18.
9
A phase 3 trial of bevacizumab in ovarian cancer.贝伐珠单抗治疗卵巢癌的 III 期临床试验。
N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验